{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:46:12Z","timestamp":1782603972342,"version":"3.54.5"},"reference-count":73,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2017,3,4]]},"DOI":"10.1080\/14737140.2017.1285702","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T20:51:18Z","timestamp":1485204678000},"page":"271-279","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":52,"title":["Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow"],"prefix":"10.1080","volume":"17","author":[{"given":"I. B.","family":"Greenwell","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University James Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3937"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236471"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.005"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70062-6"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0539"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.004"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00228"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1879"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/j.clml.2013.07.011","volume":"13","author":"Bartalucci N","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.12.004"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.21037\/sci.2016.07.02"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000113"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.245"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00224"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.09.006"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.373"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1253"},{"key":"CIT0020","unstructured":"Hutter G, Zimmermann Y, Zoellner A, et al. \u00a0Mode of action of different PI3K-inhibitors in mantle cell lymphoma. Haematologica. 2016 Jun;101(supplement 1):271-271."},{"key":"CIT0021","unstructured":"Zydelig healthcare providers page [Internet]. Gilead Sci. 2016. Available from: http:\/\/zydelig.com\/hcp\/#"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"CIT0025","volume":"34","author":"Jones JA","year":"2016","journal-title":"J Clin Oncol"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-683516"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633156"},{"issue":"3091","key":"CIT0029","first-page":"LP","volume":"124","author":"Smith SM","year":"2014","journal-title":"Blood"},{"key":"CIT0030","doi-asserted-by":"crossref","first-page":"LBA5","DOI":"10.1182\/blood.V126.23.LBA-5.LBA-5","volume":"126","author":"Zelenetz AD","year":"2015","journal-title":"Blood"},{"key":"CIT0031","unstructured":"Important drug warning (Gilead). Decreased overall survival and increased risk of serious infections in patients receiving ZYDELIG (idelalisib). [cited 2016 Aug16]. Available from: http:\/\/zydelig.com\/Content\/pdf\/Zydelig-Safety-Info-FINAL.pdf."},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707133"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-702761"},{"issue":"18030","key":"CIT0034","volume":"33","author":"Coutre S","year":"2015","journal-title":"J Clin Oncol"},{"key":"CIT0035","unstructured":"O\u2019Connor OA, Flinn IW, Lunning M, et al. Long-term follow-up of the next generation PI3K\u03b4 inhibitor TGR-1202 demonstrates safety and high response rates in NHL: integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. Haematologica. 2016 Jun;101(supplement 1):102\u2013103."},{"key":"CIT0036","unstructured":"Davids MS, Kim HT, Nicotra A, et al. Preliminary results of a phase I\/Ib study of ibrutinib in combination with TGR-1202 in patients with relapsed\/refractory CLL or MCL. \u00a0Haematologica. 2016 Jun;101(supplement 1):102\u2013103. \u00a0433-433."},{"issue":"1984","key":"CIT0037","first-page":"LP","volume":"124","author":"Burris HA","year":"2014","journal-title":"Blood"},{"issue":"7512","key":"CIT0038","volume":"34","author":"Burris HA","year":"2016","journal-title":"J Clin Oncol"},{"key":"CIT0039","doi-asserted-by":"crossref","unstructured":"Mato A, Burris III HA, Flinn IW, et al. Long-term follow-up of the next generation PI3K\u03b4 inhibitor TGR\u22121202 demonstrates a differentiated safety profile and high response rates in CLL: integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. Haematologica. 2016 Jun;101 (supplement 1):50-51.","DOI":"10.1200\/JCO.2016.34.15_suppl.7512"},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hon.2227","volume":"33","author":"Nastoupil L","year":"2015","journal-title":"Hematol Oncol"},{"issue":"2942","key":"CIT0041","first-page":"LP","volume":"126","author":"Mahadevan D","year":"2015","journal-title":"Blood"},{"key":"CIT0042","unstructured":"DUETTS: duvelisib trials in hematologic malignancies webpage [Internet]. [cited 2016 Sep 20]. Available from: http:\/\/www.duettsprogram.com\/"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3334.3334"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood.V126.23.4158.4158","volume":"126","author":"Davids MS","year":"2015","journal-title":"Blood"},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1182\/blood.V126.23.3928.3928","volume":"126","author":"Flinn IW","year":"2015","journal-title":"Blood"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-561779"},{"issue":"19052","key":"CIT0047","volume":"34","author":"Casulo C","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7578","key":"CIT0048","volume":"34","author":"Fowler NH","year":"2016","journal-title":"J Clin Oncol"},{"key":"CIT0049","unstructured":"Duvelisib hits endpoint but misses expectations in phase II iNHL study [Internet]. [cited 2016 Sep 20]. Available from: http:\/\/www.onclive.com\/web-exclusives\/duvelisib-hits-endpoint-but-misses-expectations-in-phase-ii-inhl-study"},{"key":"CIT0050","unstructured":"CHRONOS trials: ongoing clinical trials with copanlisib [Internet]. [cited 2016 Sep 20]. Available from: http:\/\/www.chronostrials.com\/#copanlisibtrials"},{"key":"CIT0051","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.V122.21.87.87","volume":"122","author":"Dreyling MH","year":"2013","journal-title":"Blood"},{"key":"CIT0052","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood.V126.23.3935.3935","volume":"126","author":"Cunningham D","year":"2015","journal-title":"Blood"},{"issue":"2610","key":"CIT0053","first-page":"5s","volume":"32","author":"Kim RD","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1718","key":"CIT0054","first-page":"LP","volume":"124","author":"Younes A","year":"2014","journal-title":"Blood"},{"key":"CIT0055","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood.V126.23.1493.1493","volume":"126","author":"Younes A","year":"2015","journal-title":"Blood"},{"issue":"2019","key":"CIT0056","first-page":"5s","volume":"32","author":"Wen PY","year":"2014","journal-title":"J Clin Oncol"},{"key":"CIT0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2016.34.15_suppl.6008","volume":"34","author":"Soulieres D","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2065","key":"CIT0058","volume":"33","author":"Shih KC","year":"2015","journal-title":"J Clin Oncol"},{"key":"CIT0059","first-page":"5025","volume":"33","author":"Armstrong AJ","year":"2015","journal-title":"ASCO Meet Abstr"},{"key":"CIT0060","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.V126.23.827.827","volume":"126","author":"Durrant ST","year":"2015","journal-title":"Blood"},{"key":"CIT0061","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1182\/blood.V126.23.5114.5114","volume":"126","author":"Maddocks KJ","year":"2015","journal-title":"Blood"},{"key":"CIT0062","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V122.21.678.678","volume":"122","author":"Lanasa MC","year":"2013","journal-title":"Blood"},{"issue":"2881","key":"CIT0063","first-page":"LP","volume":"122","author":"Kater AP","year":"2013","journal-title":"Blood"},{"key":"CIT0064","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V126.23.1495.1495","volume":"126","author":"Carlo-Stella C","year":"2015","journal-title":"Blood"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.05.017"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1042\/BST0350167"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000522"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.6598"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.011"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1038\/nature16486"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3441"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82884"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047.The"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2017.1285702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T12:57:02Z","timestamp":1598705822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2017.1285702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,6]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3,4]]}},"alternative-id":["10.1080\/14737140.2017.1285702"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2017.1285702","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}